Charter Capital Partners is proud to share that our portfolio company Swift Biosciences has been recognized as a member of SPHERES, a national open genomics consortium for the COVID-19 response. SPHERES – an acronym for the SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance – is led by the CDC.

Key components of SPHERES include:

• Monitoring important changes in the virus as it continues to circulate.
• Gaining insights to support contract tracing.
• Providing crucial information to aid in identifying diagnostic and therapeutic targets
• Advancing public health research in the areas of transmission dynamics, host response and evolution of the virus.

With extensive participation from US clinical and public health laboratories, academic institutions, and the private sector, the SPHERES consortium aims to generate information about the virus that will strengthen COVID-19 mitigation strategies. To learn more about SPHERES and view a full list of members, visit https://www.cdc.gov/coronavirus/2019-ncov/covid-data/spheres.html